Combining AI Models Improves Breast Cancer Risk Assessment

Combining artificial intelligence (AI) systems for short- and long-term breast cancer risk results in an improved cancer risk assessment, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA).

Most breast cancer screening programs take a one-size-fits-all approach and follow the same protocols when it comes to determining a woman's lifetime risk of developing breast cancer. Using mammography-based deep learning models may improve the accuracy of breast cancer risk assessment and can also lead to earlier diagnoses.

"About 1 in 10 women develop breast cancer throughout their lifetime," said study author Andreas D. Lauritzen, Ph.D., from the Department of Computer Science at the University of Copenhagen in Denmark. "In recent years, AI has been studied for the purpose of diagnosing breast cancer earlier by automatically detecting breast cancers in mammograms and measuring the risk of future breast cancer."

A variety of AI tools exist to aid in detecting cancer risk. Diagnostic AI models are trained to detect suspicious lesions on mammograms and are well suited to estimate short-term breast cancer risk.

More suitable for long-term breast cancer risk are texture AI models, capable of identifying breast density. Women with dense breast tissue are at higher risk of developing breast cancer and may benefit from supplemental MRI screening.

"It is important to enable reliable and robust assessment of breast cancer risk using information from the screening mammogram," Dr. Lauritzen said.

For this study, Dr. Lauritzen and his research team sought to identify whether a commercially available diagnostic AI tool and an AI texture model, trained separately and then subsequently combined, may improve breast cancer risk assessment.

The researchers used the diagnostic AI tool Transpara and a texture model that was developed by the researchers. A Dutch training set of over 39,000 exams was used to train the models. The short- and long-term risk models were combined using a three-layer neural network.

The combined AI model was tested on a study group of more than 119,000 women who were included in a breast cancer screening program in the Capital Region of Denmark between November 2012 and December 2015. The average age of the women was 59 years.

Compared to the diagnostic and texture models alone, the combined AI model showed an overall improved risk assessment for both interval and long-term cancer detection. Interval cancers are those that are found between routine screenings.

The model also enabled identification of women at high risk for breast cancer. Women identified by the combined model as having the 10% highest combined risk accounted for 44.1% of interval cancers and 33.7% of long-term cancers.

Using AI to identify a women’s breast cancer risk from a single mammogram will not only result in earlier cancer detection but can also improve the strain on the health care system due to the worldwide shortage of specialized breast radiologists.

"Current state-of-the-art clinical risk models require multiple tests such as blood work, genetic testing, mammogram and filling out extensive questionnaires, all of which would substantially increase the workload in the screening clinic," Dr. Lauritzen said. "Using our model, risk can be assessed with the same performance as the clinical risk models but within seconds from screening and without introducing overhead in the clinic."

Lauritzen AD, von Euler-Chelpin MC, Lynge E, Vejborg I, Nielsen M, Karssemeijer N, Lillholm M.
Assessing Breast Cancer Risk by Combining AI for Lesion Detection and Mammographic Texture.
Radiology. 2023 Aug;308(2):e230227. doi: 10.1148/radiol.230227

Most Popular Now

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

Wearable Cameras Allow AI to Detect Medi…

A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence (AI), detects potential errors in medication delivery. In a test whose...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...

New Research Shows Promise and Limitatio…

Published in JAMA Network Open, a collaborative team of researchers from the University of Minnesota Medical School, Stanford University, Beth Israel Deaconess Medical Center and the University of Virginia studied...

G-Cloud 14 Makes it Easier for NHS to Bu…

NHS organisations will be able to save valuable time and resource in the procurement of technologies that can make a significant difference to patient experience, in the latest iteration of...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

Hampshire Emergency Departments Digitise…

Emergency departments in three hospitals across Hampshire Hospitals NHS Foundation Trust have deployed Alcidion's Miya Emergency, digitising paper processes, saving clinical teams time, automating tasks, and providing trust-wide visibility of...

MEDICA HEALTH IT FORUM: Success in Maste…

11 - 14 November 2024, Düsseldorf, Germany. How can innovations help to master the great challenges and demands with which healthcare is confronted across international borders? This central question will be...

A "Chemical ChatGPT" for New M…

Researchers from the University of Bonn have trained an AI process to predict potential active ingredients with special properties. Therefore, they derived a chemical language model - a kind of...

Siemens Healthineers co-leads EU Project…

Siemens Healthineers is joining forces with more than 20 industry and public partners, including seven leading stroke hospitals, to improve stroke management for patients all over Europe. With a total...

MEDICA and COMPAMED 2024: Shining a Ligh…

11 - 14 November 2024, Düsseldorf, Germany. Christian Grosser, Director Health & Medical Technologies, is looking forward to events getting under way: "From next Monday to Thursday, we will once again...